Chronic Hepatitis News

Discontinuation of nucleos(t)ide analogue therapy for chronic hepatitis B correlated with risk for clinical relapse based on total serum level of HBV core antibodies after 2.5 years of follow-up, according to recently published data.

Liver disease-related mortality rates varied significantly by geographic region in the Untied States with some of the highest rates in the South and the West, in areas with higher Hispanic populations, and areas of lower household income, according to a recently published study.

A diagnostic score based on hepatitis B e-antigen and alanine aminotransferase was highly accurate in selecting patients for HBV therapy, according to a recent study conducted in Africa.

Results of recent study in France showed that universal hepatitis C screening was the most effective strategy and was cost-effective when treatment was initiated regardless of patient fibrosis stage.

Patients with hepatitis B showed continued improvement in bone safety after 2 years of treatment with tenofovir alafenamide compared with tenofovir disoproxil fumarate, according to a recently published study.

Patients with hepatitis C genotype 3 with compensated cirrhosis achieved a sustained virologic response rate higher than 90% after treatment with Epclusa with or without ribavirin, according to results of a recently published phase 3 study.

Hepatitis C with comorbid alcohol use disorder correlated with increased depression and anxiety, dysregulated cytokine expression, and compromised blood-brain barrier function, according to a recently published study.

The number of liver transplantations due to hepatitis C-related decompensated cirrhosis and hepatocellular carcinoma declined rapidly over the last 3 years while posttransplant survival has improved, according to data from the European Liver Transplant Registry .

This year at the Digestive Disease Meeting, physicians noted a significant increase in studies focused on the growing obesity epidemic and the gut microbiome as related to gastrointestinal complications. Additionally, the meeting included several presentations on nonalcoholic fatty liver disease treatment, outcomes in hepatitis C and hepatitis B, early detection of liver cancer, and reviews on recent obesity and gut microbiome studies.

Patients with hepatitis C genotype 1 through 4 who underwent liver transplantation had significantly high rates of sustained virologic response after treatment with Epclusa for 12 weeks, regardless of cirrhosis status, according to recently published data.